Zealand Pharma Aktie

Zealand Pharma reports that Petrelintide met the primary endpoint in the phase-2 study Zupreme-2. Weekly subcutaneous injections resulted in a statistically significant and clinically meaningful weight loss versus placebo in all three treatment groups after 28 weeks. Together with Roche, Zealand is initiating a phase-3a program consisting of Zupreme-3, Zupreme-4 and Zupreme-5. » Mere på finanzen.net

Zealand Pharma has sold its economic rights to Rusfertide to Royalty Pharma for $100 million. The payment is made in two tranches: $50 million at closing and $50 million on the first anniversary; the transaction is complete. Zealand retains a residual royalty of 0.25% on annual worldwide net sales above $1.5 billion, and Royalty Pharma receives 0.75% above that threshold. The FDA has set a target date for the approval application in the third quarter of 2026, and Takeda will take over worldwide commercialization. » Mere på de.investing.com

Jefferies downgraded Zealand Pharma from "Buy" to "Hold" and cut the price target from 505 DKK to 320 DKK, a decline of about 37%. The analyst house cited a lack of near‑term catalysts and reduced the success probability for survodutide from 60% to 40% due to ongoing tolerability concerns after Phase III data. With no company‑specific news, the downgrade was the main driver of the share drop; a short‑term recovery now depends largely on progress with petrelintide. » Mere på de.investing.com